IIT RESEARCH INSTITUTE: federal contracts won
Federal contracts of $10,000 or more awarded to this company since October 2020 (FY2021), from USAspending.gov. UEI: DGBUFQYMKWB5
33contracts won
$38,039,499total obligated
$751,371median contract
Sep 15, 2026most recent start
Agencies it works for
| Agency | Contracts | Obligated |
|---|---|---|
| Department of Health and Human Services | 31 | $35,777,714 |
| Department of Defense | 2 | $2,261,785 |
Industries (NAICS)
| NAICS | Contracts | Obligated |
|---|---|---|
| 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | 13 | $11,511,720 |
| 541712 Research and development in the physical, engineering, and life sciences (except biotechnology) | 6 | $10,088,749 |
| 541711 Research and development in biotechnology | 6 | $8,635,783 |
| 541714 Research and Development in Biotechnology (except Nanobiotechnology) | 6 | $6,568,558 |
| 541380 Testing Laboratories and Services | 1 | $646,074 |
| 541690 Other Scientific and Technical Consulting Services | 1 | $588,615 |
Where it works
Recent contracts
| Contract | Winner | Agency | Obligated | Start |
|---|---|---|---|---|
| IITRI - 2026 SF IND-ENABLING GLP TOXICOLOGY STUDIES
75N98026F00003 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$46,385 Potential value: $2,076,925 |
Sep 15, 2026 Ends: Mar 14, 2028 |
| IITRI - PA1 TASK ORDER #07
75N98026F00002 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$108,506 Potential value: $222,437 |
Sep 12, 2026 Ends: Sep 11, 2027 |
| TASK ORDER AWARD- SSL GLP AND NON-GLP TOXICOLOGY STUDIES
75N98026F00001 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$3,391,980 | Jun 25, 2026 Ends: Dec 25, 2027 |
| TOXICOLOGY STUDIES IN MICE ADMINISTERED MTX-531 - FINAL DELIVERABLES
75N91026F00001 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$68,323 | Feb 09, 2026 Ends: May 09, 2026 |
| PTTP TASK ORDER - IITRI - MS RODENT AND NON-RODENT MTD-DRF STUDIES
75N95025F00001 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$401,373 Potential value: $442,623 |
Sep 26, 2025 Ends: Sep 25, 2026 |
| FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS
75N95024F00002 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$547,006 | Sep 18, 2024 Ends: Dec 31, 2025 |
| TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102
75N91024F00003 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$627,793 Potential value: $1,945,858 |
Sep 16, 2024 Ends: Oct 31, 2026 |
| IITRI - NON-GLP DOSE RANGE FINDING (DRF) STUDIES-DEC. 2023 #2
75N95024F00004 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$201,969 | Jul 22, 2024 Ends: Jun 02, 2025 |
| TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531
75N91024F00002 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$1,790,042 | Jun 12, 2024 Ends: Jun 11, 2025 |
| IITRI -DOG MTD-DRF STUDIES-TO 4
75N95024F00003 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$224,716 | Mar 15, 2024 Ends: Dec 15, 2024 |
| IITRI - PERFORMANCE AREA 1 TO2
75N95024F00001 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$212,495 Potential value: $258,274 |
Mar 01, 2024 Ends: Feb 28, 2027 |
| IITRI - PTTP DRF BPN STUDY - TO3
75N95024F00002 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$438,148 Potential value: $473,586 |
Mar 01, 2024 Ends: Feb 28, 2025 |
| BASE TITLE: PREVENT PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TASK ORDER TITLE: NICOTINE REDUCTION THERAPY USING THE HUMAN MONOCLONAL ANTIBOD…
75N91023F00001 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$656,577 | Sep 22, 2023 Ends: Apr 25, 2025 |
| NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION
75N95022F00001 · NAICS 541712 Research and development in the physical, engineering, and life sciences (except biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$765,995 Potential value: $2,495,455 |
Sep 23, 2022 Ends: Apr 29, 2025 |
| PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
75N91022C00010 · NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$3,452,984 Potential value: $9,353,817 |
Apr 01, 2022 Ends: Mar 31, 2027 |
| PRECLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES
75N93022F00001 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$1,883,524 Potential value: $10,359,384 |
Dec 10, 2021 Ends: Jul 01, 2022 |
| EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER
75N91021F00001 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$532,562 | Sep 06, 2021 Ends: Jul 31, 2024 |
| TECHNLOLOGY TRANSFER ASSAYS
W911QY21C0014 · NAICS 541380 Testing Laboratories and Services · Chicago, IL |
— | Department of Defense Department of the Army |
$646,074 Potential value: $8,621,174 |
Nov 30, 2020 Ends: Nov 29, 2021 |
| NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020…
75N95020F00003 · NAICS 541712 Research and development in the physical, engineering, and life sciences (except biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$751,371 | Sep 25, 2020 Ends: Dec 31, 2024 |
| SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLIN…
75N91020F00001 · NAICS 541690 Other Scientific and Technical Consulting Services · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$588,615 Potential value: $2,425,017 |
Sep 23, 2020 Ends: Aug 31, 2022 |
| TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022
75N91020F00001 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$1,161,990 Potential value: $1,405,361 |
Sep 21, 2020 Ends: Jan 31, 2026 |
| TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2…
75N95020F00002 · NAICS 541712 Research and development in the physical, engineering, and life sciences (except biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$2,373,515 | Sep 17, 2020 Ends: Oct 31, 2025 |
| COVID-19 RELATED STUDY INVOLVING DOGS
75N91020F00002 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$597,893 | Sep 16, 2020 Ends: Mar 15, 2021 |
| NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.
75N95020F00001 · NAICS 541712 Research and development in the physical, engineering, and life sciences (except biotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$3,053,804 | Sep 16, 2020 Ends: Sep 30, 2024 |
| PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR …
75N91020F00001 · NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) · Chicago, IL |
— | Department of Health and Human Services National Institutes of Health |
$1,736,011 | Sep 08, 2020 Ends: May 07, 2025 |
Source: USAspending.gov (prime contract awards of $10,000 or more). Values are amounts obligated to date. Recent months can still change as agencies report late.